Phase II MAvERIC Shows Sustained Pain, Inflammation Reductions; Phase III Enrollment Tops 75%
Cardiol Therapeutics reported that its Phase II MAvERIC study of CardiolRx achieved rapid, sustained reductions in pericarditis pain and inflammation, cutting recurrence rates with favorable safety. Results accepted by the Journal of the American Heart Association validate CardiolRx and bolster the ongoing Phase III MAVERIC trial, now over 75% enrolled.
1. Phase II Results Published
Cardiol Therapeutics secured acceptance for publication of its Phase II MAvERIC results in the Journal of the American Heart Association. The peer-reviewed article highlights the clinical impact of CardiolRx™, marking the first independent validation of the trial’s findings.
2. Efficacy Outcomes
The Phase II study demonstrated rapid and sustained reductions in pericarditis pain and inflammation, while cutting recurrence rates per year. Patients experienced a substantial decrease in episode frequency alongside a favorable safety and tolerability profile without immunosuppressive therapy.
3. Phase III MAVERIC Progress
The pivotal Phase III MAVERIC trial has now surpassed 75% patient enrollment, reflecting strong recruitment momentum. These interim milestones support trial integrity and set the stage for final efficacy and safety readouts.
4. Development Outlook
With orphan drug designation for pericarditis and a pipeline including CRD-38 for inflammatory heart disease, Cardiol Therapeutics aims to complete Phase III MAVERIC and engage in regulatory discussions to address recurrent pericarditis, an area of significant unmet medical need.